The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered at risk. This article provides an assessment of nitrosamine contamination, specifically in potential risks between these product types.
By downloading this content, I agree that SGS can use my data for the purposes of dealing with my request in accordance with the SGS Online Privacy Statement. SGS may also contact me with information on webinars, news, and events, and their experts can contact me about testing solutions.